Trial Outcomes & Findings for European Safety Registry in Ulcerative Colitis (P04808) (NCT NCT00705484)
NCT ID: NCT00705484
Last Updated: 2018-08-27
Results Overview
The nine AE categories are as follows: 1) Serious infections, including infections listed as Serious AEs, tuberculosis, invasive fungal infections, other opportunistic infections, salmonellosis; 2) Infusion-related reactions including delayed hypersensitivity and anaphylactic reactions, and change in severity of infusion-related reactions over time; 3) Fatalities, analyzed by cause; 4)Worsening or new congestive heart failure; 5) Central and peripheral demyelinating neurological disorders; 6) Hematologic conditions such as idiopathic thrombocytopenic purpura, thrombotic thrombocytopenic purpura, thrombocytopenia, pancytopenia, granulocytopenia, leucopenia, hemolytic anemia, aplastic anemia, and thromboembolic events; 7) Malignancies, especially lymphoma, colorectal cancer, and skin cancer; 8) Autoimmune disorders such as lupus and lupus-like syndromes; 9) Hepatobiliary events including autoimmune hepatitis, primary sclerosing cholangitis, and liver function test abnormalities.
Recruitment status
COMPLETED
Target enrollment
2239 participants
Primary outcome timeframe
Up to 5 years.
Results posted on
2018-08-27
Participant Flow
Participant milestones
| Measure |
Remicade Group
Participants with no prior exposure to Remicade or who have been treated with Remicade in the past, who at the time of enrollment are scheduled to receive Remicade within 30 days of the Baseline Visit. Participants who have been treated in the past with Remicade must have a Remicade-free interval of no less than 90 days from the date of the next expected infusion.
|
Standard Therapy Group
Participants who are scheduled to receive standard therapy (defined as initiation or dose-increase of corticosteroids and/or immunosuppressants) that does not include Remicade. Standard therapy participants must not have previously received Remicade for Ulcerative Colitis (UC) or any other condition.
|
|---|---|---|
|
Overall Study
STARTED
|
1059
|
1180
|
|
Overall Study
Follow-up Period
|
1059
|
296
|
|
Overall Study
COMPLETED
|
677
|
772
|
|
Overall Study
NOT COMPLETED
|
382
|
408
|
Reasons for withdrawal
| Measure |
Remicade Group
Participants with no prior exposure to Remicade or who have been treated with Remicade in the past, who at the time of enrollment are scheduled to receive Remicade within 30 days of the Baseline Visit. Participants who have been treated in the past with Remicade must have a Remicade-free interval of no less than 90 days from the date of the next expected infusion.
|
Standard Therapy Group
Participants who are scheduled to receive standard therapy (defined as initiation or dose-increase of corticosteroids and/or immunosuppressants) that does not include Remicade. Standard therapy participants must not have previously received Remicade for Ulcerative Colitis (UC) or any other condition.
|
|---|---|---|
|
Overall Study
Adverse Event
|
28
|
27
|
|
Overall Study
Lost to Follow-up
|
169
|
250
|
|
Overall Study
Withdrawal by Subject
|
96
|
72
|
|
Overall Study
Administrative
|
89
|
59
|
Baseline Characteristics
European Safety Registry in Ulcerative Colitis (P04808)
Baseline characteristics by cohort
| Measure |
Remicade Group
n=1059 Participants
Participants with no prior exposure to Remicade or who have been treated with Remicade in the past, who at the time of enrollment are scheduled to receive Remicade within 30 days of the Baseline Visit. Participants who have been treated in the past with Remicade must have a Remicade-free interval of no less than 90 days from the date of the next expected infusion.
|
Standard Therapy Group
n=1180 Participants
Participants who are scheduled to receive standard therapy (defined as initiation or dose-increase of corticosteroids and/or immunosuppressants) that does not include Remicade. Standard therapy participants must not have previously received Remicade for UC or any other condition.
|
Total
n=2239 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Continuous
|
40.3 Years
STANDARD_DEVIATION 14.24 • n=5 Participants
|
42.0 Years
STANDARD_DEVIATION 15.44 • n=7 Participants
|
41.2 Years
STANDARD_DEVIATION 14.91 • n=5 Participants
|
|
Sex: Female, Male
Female
|
464 Participants
n=5 Participants
|
541 Participants
n=7 Participants
|
1005 Participants
n=5 Participants
|
|
Sex: Female, Male
Male
|
595 Participants
n=5 Participants
|
639 Participants
n=7 Participants
|
1234 Participants
n=5 Participants
|
PRIMARY outcome
Timeframe: Up to 5 years.Population: All enrolled participants. The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
The nine AE categories are as follows: 1) Serious infections, including infections listed as Serious AEs, tuberculosis, invasive fungal infections, other opportunistic infections, salmonellosis; 2) Infusion-related reactions including delayed hypersensitivity and anaphylactic reactions, and change in severity of infusion-related reactions over time; 3) Fatalities, analyzed by cause; 4)Worsening or new congestive heart failure; 5) Central and peripheral demyelinating neurological disorders; 6) Hematologic conditions such as idiopathic thrombocytopenic purpura, thrombotic thrombocytopenic purpura, thrombocytopenia, pancytopenia, granulocytopenia, leucopenia, hemolytic anemia, aplastic anemia, and thromboembolic events; 7) Malignancies, especially lymphoma, colorectal cancer, and skin cancer; 8) Autoimmune disorders such as lupus and lupus-like syndromes; 9) Hepatobiliary events including autoimmune hepatitis, primary sclerosing cholangitis, and liver function test abnormalities.
Outcome measures
| Measure |
Remicade Group
n=1059 Participants
Participants with no prior exposure to Remicade or who have been treated with Remicade in the past, who at the time of enrollment are scheduled to receive Remicade within 30 days of the Baseline Visit. Participants who have been treated in the past with Remicade must have a Remicade-free interval of no less than 90 days from the date of the next expected infusion.
|
Standard Therapy Group
n=1180 Participants
Participants who are scheduled to receive standard therapy (defined as initiation or dose-increase of corticosteroids and/or immunosuppressants) that does not include Remicade. Standard therapy participants must not have previously received Remicade for UC or any other condition.
|
Switched to Remicade Group
n=296 Participants
Participants who started the registry on standard therapy but subsequently switched to Remicade. AEs were counted after the switch to Remicade.
|
|---|---|---|---|
|
Percentage of Participants Within Each of Nine Pre-specified Adverse Event (AE) Categories
Serious Infection
|
9.1 Percentage of participants
|
3.4 Percentage of participants
|
10.5 Percentage of participants
|
|
Percentage of Participants Within Each of Nine Pre-specified Adverse Event (AE) Categories
Infusion-Related Reactions
|
13.0 Percentage of participants
|
0.2 Percentage of participants
|
8.8 Percentage of participants
|
|
Percentage of Participants Within Each of Nine Pre-specified Adverse Event (AE) Categories
Congestive Heart Failure
|
0.3 Percentage of participants
|
0.3 Percentage of participants
|
0.3 Percentage of participants
|
|
Percentage of Participants Within Each of Nine Pre-specified Adverse Event (AE) Categories
Demyelinating Neurological Disorders
|
0.1 Percentage of participants
|
0.2 Percentage of participants
|
0.3 Percentage of participants
|
|
Percentage of Participants Within Each of Nine Pre-specified Adverse Event (AE) Categories
Hematologic Conditions
|
4.2 Percentage of participants
|
2.2 Percentage of participants
|
4.1 Percentage of participants
|
|
Percentage of Participants Within Each of Nine Pre-specified Adverse Event (AE) Categories
Lymphoproliferative Disorders/ Malignancies
|
3.7 Percentage of participants
|
2.9 Percentage of participants
|
1.7 Percentage of participants
|
|
Percentage of Participants Within Each of Nine Pre-specified Adverse Event (AE) Categories
Autoimmune Disorders
|
2.2 Percentage of participants
|
1.1 Percentage of participants
|
2.4 Percentage of participants
|
|
Percentage of Participants Within Each of Nine Pre-specified Adverse Event (AE) Categories
Hepatobiliary Events
|
4.4 Percentage of participants
|
3.6 Percentage of participants
|
4.1 Percentage of participants
|
|
Percentage of Participants Within Each of Nine Pre-specified Adverse Event (AE) Categories
Fatalities
|
0.8 Percentage of participants
|
1.3 Percentage of participants
|
0.3 Percentage of participants
|
Adverse Events
Remicade Group
Serious events: 439 serious events
Other events: 321 other events
Deaths: 0 deaths
Standard Therapy Group
Serious events: 294 serious events
Other events: 173 other events
Deaths: 0 deaths
Switched to Remicade Group
Serious events: 102 serious events
Other events: 70 other events
Deaths: 0 deaths
Serious adverse events
| Measure |
Remicade Group
n=1059 participants at risk
Participants with no prior exposure to Remicade or who have been treated with Remicade in the past, who at the time of enrollment are scheduled to receive Remicade within 30 days of the Baseline Visit. Participants who have been treated in the past with Remicade must have a Remicade-free interval of no less than 90 days from the date of the next expected infusion.
|
Standard Therapy Group
n=1180 participants at risk
Participants who are scheduled to receive standard therapy (defined as initiation or dose-increase of corticosteroids and/or immunosuppressants) that does not include Remicade. Standard therapy participants must not have previously received Remicade for UC or any other condition.
|
Switched to Remicade Group
n=296 participants at risk
Participants who started in the Standard Therapy Group but switched over to Remicade. AEs were counted after the switch to Remicade.
|
|---|---|---|---|
|
General disorders
Influenza Like Illness
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
General disorders
Malaise
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
General disorders
Obstruction
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
General disorders
Pain
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
General disorders
Pyrexia
|
1.3%
14/1059 • Number of events 14 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.17%
2/1180 • Number of events 4 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
1.4%
4/296 • Number of events 4 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
General disorders
Strangulated Hernia
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
General disorders
Sudden Death
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
General disorders
Surgical Failure
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
General disorders
Treatment Failure
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
General disorders
Vascular Stent Restenosis
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.17%
2/1180 • Number of events 2 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Hepatobiliary disorders
Autoimmune Hepatitis
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Hepatobiliary disorders
Bile Duct Stenosis
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Hepatobiliary disorders
Cholangitis
|
0.19%
2/1059 • Number of events 3 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Hepatobiliary disorders
Cholangitis Acute
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Hepatobiliary disorders
Cholangitis Sclerosing
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.17%
2/1180 • Number of events 2 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Hepatobiliary disorders
Cholecystitis
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Hepatobiliary disorders
Cholelithiasis
|
0.28%
3/1059 • Number of events 3 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
4/1180 • Number of events 4 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Hepatobiliary disorders
Cholestasis
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Hepatobiliary disorders
Cholestasis Of Pregnancy
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Hepatobiliary disorders
Drug-Induced Liver Injury
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Hepatobiliary disorders
Hepatitis Cholestatic
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Hepatobiliary disorders
Hepatitis Toxic
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Basal Cell Carcinoma
|
0.28%
3/1059 • Number of events 4 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Hepatobiliary disorders
Hyperbilirubinaemia
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Hepatobiliary disorders
Liver Injury
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Hepatobiliary disorders
Portal Vein Thrombosis
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Immune system disorders
Anaphylactic Reaction
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Immune system disorders
Drug Hypersensitivity
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Immune system disorders
Hypersensitivity
|
0.19%
2/1059 • Number of events 2 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Immune system disorders
Serum Sickness
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Infections and infestations
Abdominal Abscess
|
0.19%
2/1059 • Number of events 2 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Infections and infestations
Abdominal Wall Abscess
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Infections and infestations
Abscess
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Infections and infestations
Abscess Jaw
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Infections and infestations
Acinetobacter Infection
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Infections and infestations
Anal Abscess
|
0.57%
6/1059 • Number of events 9 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Infections and infestations
Appendicitis
|
0.19%
2/1059 • Number of events 2 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.17%
2/1180 • Number of events 2 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
1.0%
3/296 • Number of events 3 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Infections and infestations
Arthritis Bacterial
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Infections and infestations
Atypical Pneumonia
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Infections and infestations
Bacteraemia
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Infections and infestations
Bartholinitis
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Infections and infestations
Biliary Sepsis
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Infections and infestations
Breast Abscess
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Infections and infestations
Bronchitis
|
0.28%
3/1059 • Number of events 3 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Psychiatric disorders
Completed Suicide
|
0.19%
2/1059 • Number of events 2 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Renal and urinary disorders
Acute Prerenal Failure
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Infections and infestations
Bronchopulmonary Aspergillosis
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Infections and infestations
Campylobacter Infection
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.17%
2/1180 • Number of events 2 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Infections and infestations
Candida Endophthalmitis
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Infections and infestations
Candida Sepsis
|
0.19%
2/1059 • Number of events 2 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Infections and infestations
Cellulitis
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Infections and infestations
Clostridial Infection
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Infections and infestations
Clostridium Difficile Colitis
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.17%
2/1180 • Number of events 2 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Infections and infestations
Clostridium Difficile Infection
|
0.47%
5/1059 • Number of events 5 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.17%
2/1180 • Number of events 2 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.68%
2/296 • Number of events 2 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Infections and infestations
Cystitis
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Infections and infestations
Cytomegalovirus Colitis
|
0.38%
4/1059 • Number of events 4 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.17%
2/1180 • Number of events 2 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Infections and infestations
Cytomegalovirus Infection
|
0.57%
6/1059 • Number of events 6 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 2 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Infections and infestations
Device Related Infection
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Infections and infestations
Diverticulitis
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.17%
2/1180 • Number of events 5 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Infections and infestations
Dysentery
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Infections and infestations
Ear Infection
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Blood and lymphatic system disorders
Anaemia
|
0.57%
6/1059 • Number of events 6 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.17%
2/1180 • Number of events 2 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.68%
2/296 • Number of events 3 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Blood and lymphatic system disorders
Bicytopenia
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Blood and lymphatic system disorders
Bone Marrow Failure
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Blood and lymphatic system disorders
Haemolytic Anaemia
|
0.19%
2/1059 • Number of events 2 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Blood and lymphatic system disorders
Haemorrhagic Anaemia
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Blood and lymphatic system disorders
Immune Thrombocytopenic Purpura
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Blood and lymphatic system disorders
Iron Deficiency Anaemia
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Blood and lymphatic system disorders
Leukopenia
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.68%
2/296 • Number of events 2 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Blood and lymphatic system disorders
Lymphadenitis
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Blood and lymphatic system disorders
Lymphadenopathy
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Blood and lymphatic system disorders
Neutropenia
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Blood and lymphatic system disorders
Normochromic Normocytic Anaemia
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Blood and lymphatic system disorders
Pancytopenia
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Blood and lymphatic system disorders
Thrombocytopenia
|
0.09%
1/1059 • Number of events 2 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Cardiac disorders
Acute Coronary Syndrome
|
0.28%
3/1059 • Number of events 3 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Cardiac disorders
Acute Myocardial Infarction
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Cardiac disorders
Angina Pectoris
|
0.19%
2/1059 • Number of events 2 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Cardiac disorders
Angina Unstable
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 2 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Cardiac disorders
Aortic Valve Incompetence
|
0.09%
1/1059 • Number of events 2 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Cardiac disorders
Arrhythmia
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Cardiac disorders
Atrial Fibrillation
|
0.19%
2/1059 • Number of events 4 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.17%
2/1180 • Number of events 2 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Cardiac disorders
Bradycardia
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Cardiac disorders
Cardiac Failure
|
0.19%
2/1059 • Number of events 2 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Cardiac disorders
Cardiac Failure Congestive
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Cardiac disorders
Coronary Artery Disease
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.25%
3/1180 • Number of events 3 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Cardiac disorders
Heart Valve Incompetence
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Cardiac disorders
Left Ventricular Dysfunction
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Cardiac disorders
Myocardial Infarction
|
0.19%
2/1059 • Number of events 2 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.51%
6/1180 • Number of events 7 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.68%
2/296 • Number of events 2 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Cardiac disorders
Myocardial Ischaemia
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Cardiac disorders
Myocarditis
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Cardiac disorders
Palpitations
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Cardiac disorders
Pericarditis
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Cardiac disorders
Prinzmetal Angina
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Cardiac disorders
Sinus Node Dysfunction
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Cardiac disorders
Supraventricular Tachycardia
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Cardiac disorders
Tachycardia
|
0.19%
2/1059 • Number of events 2 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Cardiac disorders
Ventricular Tachycardia
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Ear and labyrinth disorders
Deafness
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Ear and labyrinth disorders
Meniere's Disease
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Ear and labyrinth disorders
Vertigo
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Endocrine disorders
Basedow's Disease
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Eye disorders
Cataract
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 2 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Eye disorders
Conjunctivitis Allergic
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Eye disorders
Corneal Scar
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Eye disorders
Endocrine Ophthalmopathy
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Eye disorders
Eye Disorder
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Gastrointestinal disorders
Abdominal Discomfort
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Gastrointestinal disorders
Abdominal Hernia
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Gastrointestinal disorders
Abdominal Hernia Obstructive
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Gastrointestinal disorders
Abdominal Pain
|
0.94%
10/1059 • Number of events 10 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
1.2%
14/1180 • Number of events 17 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
1.7%
5/296 • Number of events 5 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Gastrointestinal disorders
Abdominal Pain Lower
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Gastrointestinal disorders
Abdominal Pain Upper
|
0.19%
2/1059 • Number of events 2 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Gastrointestinal disorders
Abdominal Wall Haematoma
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Gastrointestinal disorders
Acute Abdomen
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Gastrointestinal disorders
Anal Fissure
|
0.19%
2/1059 • Number of events 2 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Gastrointestinal disorders
Anal Fistula
|
0.57%
6/1059 • Number of events 6 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.25%
3/1180 • Number of events 3 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.68%
2/296 • Number of events 2 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Gastrointestinal disorders
Anal Haemorrhage
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Gastrointestinal disorders
Anal Incontinence
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Gastrointestinal disorders
Anal Stenosis
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Gastrointestinal disorders
Anal Ulcer
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Gastrointestinal disorders
Anorectal Discomfort
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Gastrointestinal disorders
Anorectal Disorder
|
0.28%
3/1059 • Number of events 3 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Gastrointestinal disorders
Aphthous Ulcer
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Gastrointestinal disorders
Colitis
|
2.5%
27/1059 • Number of events 29 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
1.3%
15/1180 • Number of events 16 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Gastrointestinal disorders
Colitis Ulcerative
|
22.9%
243/1059 • Number of events 370 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
11.2%
132/1180 • Number of events 168 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
15.9%
47/296 • Number of events 62 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Gastrointestinal disorders
Colon Dysplasia
|
0.19%
2/1059 • Number of events 2 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.17%
2/1180 • Number of events 2 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Gastrointestinal disorders
Constipation
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Gastrointestinal disorders
Crohn's Disease
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.17%
2/1180 • Number of events 2 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Gastrointestinal disorders
Diarrhoea
|
0.94%
10/1059 • Number of events 10 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.25%
3/1180 • Number of events 3 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Gastrointestinal disorders
Diarrhoea Haemorrhagic
|
0.28%
3/1059 • Number of events 5 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Gastrointestinal disorders
Diverticular Perforation
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 4 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Gastrointestinal disorders
Duodenal Ulcer
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Gastrointestinal disorders
Dysphagia
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Gastrointestinal disorders
Enteritis
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Gastrointestinal disorders
Enterocolitis Haemorrhagic
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Gastrointestinal disorders
Enterocutaneous Fistula
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Gastrointestinal disorders
Eosinophilic Oesophagitis
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Gastrointestinal disorders
Faecaloma
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Gastrointestinal disorders
Food Poisoning
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Gastrointestinal disorders
Gastric Atony
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Gastrointestinal disorders
Gastric Polyps
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Gastrointestinal disorders
Gastrointestinal Disorder
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 2 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Gastrointestinal disorders
Gastrointestinal Dysplasia
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 2 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Gastrointestinal disorders
Gastrointestinal Haemorrhage
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Gastrointestinal disorders
Gastrointestinal Inflammation
|
0.19%
2/1059 • Number of events 3 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Gastrointestinal disorders
Gastrointestinal Pain
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Gastrointestinal disorders
Gastrointestinal Polyp Haemorrhage
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Gastrointestinal disorders
Haematochezia
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Gastrointestinal disorders
Haemorrhoids
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.17%
2/1180 • Number of events 2 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Gastrointestinal disorders
Haemorrhoids Thrombosed
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Gastrointestinal disorders
Ileal Stenosis
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Gastrointestinal disorders
Ileus
|
0.85%
9/1059 • Number of events 10 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Gastrointestinal disorders
Inflammatory Bowel Disease
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Gastrointestinal disorders
Inguinal Hernia
|
0.19%
2/1059 • Number of events 2 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Gastrointestinal disorders
Intestinal Dilatation
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Gastrointestinal disorders
Intestinal Haemorrhage
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Gastrointestinal disorders
Intestinal Obstruction
|
0.38%
4/1059 • Number of events 4 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.25%
3/1180 • Number of events 3 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.68%
2/296 • Number of events 2 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Gastrointestinal disorders
Intestinal Perforation
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Gastrointestinal disorders
Intestinal Stenosis
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Gastrointestinal disorders
Intra-Abdominal Fluid Collection
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Gastrointestinal disorders
Intra-Abdominal Haemorrhage
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Gastrointestinal disorders
Jejunal Perforation
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Gastrointestinal disorders
Large Intestinal Stenosis
|
0.28%
3/1059 • Number of events 3 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Gastrointestinal disorders
Large Intestine Perforation
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Gastrointestinal disorders
Large Intestine Polyp
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Gastrointestinal disorders
Megacolon
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Gastrointestinal disorders
Mesenteric Haemorrhage
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Gastrointestinal disorders
Nausea
|
—
0/0 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Gastrointestinal disorders
Oedematous Pancreatitis
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Gastrointestinal disorders
Oesophageal Food Impaction
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Gastrointestinal disorders
Pancreatitis
|
0.85%
9/1059 • Number of events 9 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.68%
8/1180 • Number of events 8 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Gastrointestinal disorders
Pancreatitis Acute
|
0.19%
2/1059 • Number of events 3 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.25%
3/1180 • Number of events 3 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Gastrointestinal disorders
Peritoneal Haemorrhage
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Gastrointestinal disorders
Pouchitis
|
0.66%
7/1059 • Number of events 9 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Gastrointestinal disorders
Proctalgia
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.25%
3/1180 • Number of events 4 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Gastrointestinal disorders
Proctitis
|
0.28%
3/1059 • Number of events 3 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Gastrointestinal disorders
Rectal Haemorrhage
|
0.57%
6/1059 • Number of events 6 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
4/1180 • Number of events 4 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Gastrointestinal disorders
Rectal Lesion
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Gastrointestinal disorders
Rectal Prolapse
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Gastrointestinal disorders
Rectal Stenosis
|
0.19%
2/1059 • Number of events 2 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.17%
2/1180 • Number of events 2 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Gastrointestinal disorders
Small Intestinal Obstruction
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Gastrointestinal disorders
Small Intestinal Perforation
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Gastrointestinal disorders
Subileus
|
0.47%
5/1059 • Number of events 5 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Gastrointestinal disorders
Umbilical Hernia
|
0.19%
2/1059 • Number of events 2 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Gastrointestinal disorders
Upper Gastrointestinal Haemorrhage
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Gastrointestinal disorders
Vomiting
|
0.38%
4/1059 • Number of events 5 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.17%
2/1180 • Number of events 2 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
General disorders
Asthenia
|
0.38%
4/1059 • Number of events 4 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
General disorders
Catheter Site Inflammation
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
General disorders
Chest Discomfort
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
General disorders
Chest Pain
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.17%
2/1180 • Number of events 2 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
General disorders
Drug Ineffective
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
General disorders
Drug Intolerance
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
General disorders
Dysplasia
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
General disorders
Fatigue
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
General disorders
Gait Disturbance
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
General disorders
General Physical Health Deterioration
|
0.28%
3/1059 • Number of events 5 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
General disorders
Hyperthermia
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
General disorders
Impaired Healing
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.17%
2/1180 • Number of events 3 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Infections and infestations
Eczema Infected
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Infections and infestations
Encephalitis
|
0.19%
2/1059 • Number of events 2 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Infections and infestations
Encephalitis Cytomegalovirus
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Infections and infestations
Endophthalmitis
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Infections and infestations
Enterococcal Infection
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Infections and infestations
Erysipelas
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Infections and infestations
Escherichia Infection
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Infections and infestations
Gallbladder Empyema
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Infections and infestations
Gastroenteritis
|
0.47%
5/1059 • Number of events 5 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
4/1180 • Number of events 4 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Infections and infestations
Gastroenteritis Clostridial
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Infections and infestations
Gastroenteritis Salmonella
|
0.19%
2/1059 • Number of events 2 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Infections and infestations
Gastroenteritis Viral
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.25%
3/1180 • Number of events 3 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Infections and infestations
Hepatitis C
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Infections and infestations
Herpes Zoster
|
0.28%
3/1059 • Number of events 3 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Infections and infestations
Incision Site Abscess
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Infections and infestations
Infection
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Infections and infestations
Infectious Mononucleosis
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Infections and infestations
Keratitis Bacterial
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Infections and infestations
Klebsiella Infection
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Infections and infestations
Laryngitis
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Infections and infestations
Listeria Sepsis
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Infections and infestations
Lung Abscess
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Infections and infestations
Lung Infection
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Infections and infestations
Meningitis Viral
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Infections and infestations
Nasopharyngitis
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Infections and infestations
Orchitis
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Infections and infestations
Perineal Abscess
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Infections and infestations
Peritonitis
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Infections and infestations
Pharyngotonsillitis
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Infections and infestations
Pilonidal Cyst
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Infections and infestations
Pneumocystis Jirovecii Pneumonia
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Infections and infestations
Pneumonia
|
1.4%
15/1059 • Number of events 18 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.42%
5/1180 • Number of events 5 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
1.4%
4/296 • Number of events 4 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Infections and infestations
Pneumonia Bacterial
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Infections and infestations
Pneumonia Escherichia
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Infections and infestations
Pneumonia Legionella
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Infections and infestations
Post Procedural Sepsis
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Infections and infestations
Postoperative Abscess
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Infections and infestations
Postoperative Wound Infection
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Infections and infestations
Proctitis Infectious
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Infections and infestations
Pulmonary Tuberculosis
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Infections and infestations
Purulent Discharge
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Infections and infestations
Pyelitis
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Infections and infestations
Pyelonephritis
|
0.19%
2/1059 • Number of events 3 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 2 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Infections and infestations
Pyelonephritis Acute
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Infections and infestations
Rectal Abscess
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Infections and infestations
Relapsing Fever
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Infections and infestations
Renal Abscess
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Infections and infestations
Respiratory Moniliasis
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Infections and infestations
Retinitis
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 2 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Infections and infestations
Rotavirus Infection
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Infections and infestations
Pelvic Abscess
|
0.28%
3/1059 • Number of events 4 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Infections and infestations
Salmonellosis
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Infections and infestations
Sepsis
|
0.66%
7/1059 • Number of events 7 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.25%
3/1180 • Number of events 3 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Infections and infestations
Septic Shock
|
0.19%
2/1059 • Number of events 2 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.17%
2/1180 • Number of events 2 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Infections and infestations
Sinusitis
|
0.19%
2/1059 • Number of events 2 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Infections and infestations
Staphylococcal Infection
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Infections and infestations
Streptococcal Bacteraemia
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Infections and infestations
Subcutaneous Abscess
|
0.19%
2/1059 • Number of events 2 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.68%
2/296 • Number of events 2 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Infections and infestations
Tick-Borne Viral Encephalitis
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Infections and infestations
Tonsillitis Streptococcal
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Infections and infestations
Tuberculosis
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Infections and infestations
Tubo-Ovarian Abscess
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Infections and infestations
Tularaemia
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Infections and infestations
Upper Respiratory Tract Infection
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Infections and infestations
Urinary Tract Infection
|
0.19%
2/1059 • Number of events 2 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 2 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Infections and infestations
Viral Infection
|
0.19%
2/1059 • Number of events 2 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Infections and infestations
Wound Infection
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Infections and infestations
Wound Infection Bacterial
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Injury, poisoning and procedural complications
Anastomotic Complication
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Injury, poisoning and procedural complications
Anastomotic Fistula
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Injury, poisoning and procedural complications
Anastomotic Leak
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Injury, poisoning and procedural complications
Anastomotic Stenosis
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Injury, poisoning and procedural complications
Ankle Fracture
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Injury, poisoning and procedural complications
Decompression Sickness
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Injury, poisoning and procedural complications
Fall
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 2 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Injury, poisoning and procedural complications
Femoral Neck Fracture
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Injury, poisoning and procedural complications
Femur Fracture
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Injury, poisoning and procedural complications
Gastrointestinal Stoma Complication
|
0.09%
1/1059 • Number of events 2 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Injury, poisoning and procedural complications
Hand Fracture
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Injury, poisoning and procedural complications
Humerus Fracture
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Injury, poisoning and procedural complications
Incisional Hernia
|
0.19%
2/1059 • Number of events 2 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Injury, poisoning and procedural complications
Infusion Related Reaction
|
0.19%
2/1059 • Number of events 2 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Injury, poisoning and procedural complications
Intentional Overdose
|
0.47%
5/1059 • Number of events 5 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Injury, poisoning and procedural complications
Intestinal Anastomosis Complication
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Injury, poisoning and procedural complications
Joint Dislocation
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Injury, poisoning and procedural complications
Joint Injury
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Injury, poisoning and procedural complications
Ligament Rupture
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 2 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Injury, poisoning and procedural complications
Ligament Sprain
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Injury, poisoning and procedural complications
Lumbar Vertebral Fracture
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Injury, poisoning and procedural complications
Meniscus Injury
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 2 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Injury, poisoning and procedural complications
Open Globe Injury
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Injury, poisoning and procedural complications
Pneumothorax Traumatic
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Injury, poisoning and procedural complications
Post Procedural Complication
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Injury, poisoning and procedural complications
Post Procedural Diarrhoea
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Injury, poisoning and procedural complications
Post Procedural Haemorrhage
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Injury, poisoning and procedural complications
Post Procedural Inflammation
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Injury, poisoning and procedural complications
Postoperative Hernia
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.17%
2/1180 • Number of events 2 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Injury, poisoning and procedural complications
Postoperative Ileus
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Injury, poisoning and procedural complications
Postoperative Wound Complication
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Injury, poisoning and procedural complications
Procedural Pain
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Injury, poisoning and procedural complications
Radius Fracture
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Injury, poisoning and procedural complications
Road Traffic Accident
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Injury, poisoning and procedural complications
Scar
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Injury, poisoning and procedural complications
Spinal Compression Fracture
|
0.19%
2/1059 • Number of events 2 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Injury, poisoning and procedural complications
Stoma Complication
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Injury, poisoning and procedural complications
Stoma Site Discomfort
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Injury, poisoning and procedural complications
Stoma Site Inflammation
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Injury, poisoning and procedural complications
Stomal Hernia
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.68%
2/296 • Number of events 2 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Injury, poisoning and procedural complications
Tendon Rupture
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Injury, poisoning and procedural complications
Thoracic Vertebral Fracture
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Injury, poisoning and procedural complications
Tibia Fracture
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Injury, poisoning and procedural complications
Toxicity To Various Agents
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Injury, poisoning and procedural complications
Upper Limb Fracture
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Injury, poisoning and procedural complications
Wound Dehiscence
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Injury, poisoning and procedural complications
Wound Evisceration
|
0.19%
2/1059 • Number of events 2 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Investigations
Biopsy Lymph Gland
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Investigations
Blood Bilirubin Increased
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Investigations
Blood Creatinine Increased
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Investigations
Blood Magnesium Decreased
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Investigations
Blood Parathyroid Hormone Increased
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Investigations
Clostridium Test Positive
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Investigations
Cytomegalovirus Test Positive
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Investigations
Endobronchial Ultrasound
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Investigations
Foetal Heart Rate Abnormal
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Investigations
Weight Decreased
|
0.19%
2/1059 • Number of events 2 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Metabolism and nutrition disorders
Cachexia
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Metabolism and nutrition disorders
Decreased Appetite
|
0.19%
2/1059 • Number of events 2 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Metabolism and nutrition disorders
Dehydration
|
0.47%
5/1059 • Number of events 5 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
1.4%
4/296 • Number of events 6 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Metabolism and nutrition disorders
Diabetes Mellitus Inadequate Control
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Metabolism and nutrition disorders
Electrolyte Imbalance
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Metabolism and nutrition disorders
Hyperglycaemia
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Metabolism and nutrition disorders
Hypoalbuminaemia
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Metabolism and nutrition disorders
Hyponatraemia
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Metabolism and nutrition disorders
Malnutrition
|
0.19%
2/1059 • Number of events 2 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Metabolism and nutrition disorders
Obesity
|
0.19%
2/1059 • Number of events 2 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Metabolism and nutrition disorders
Type 2 Diabetes Mellitus
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Musculoskeletal and connective tissue disorders
Ankylosing Spondylitis
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Musculoskeletal and connective tissue disorders
Arthralgia
|
0.28%
3/1059 • Number of events 3 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.25%
3/1180 • Number of events 3 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Musculoskeletal and connective tissue disorders
Arthritis
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.25%
3/1180 • Number of events 3 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Musculoskeletal and connective tissue disorders
Back Pain
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Musculoskeletal and connective tissue disorders
Bursitis
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Musculoskeletal and connective tissue disorders
Cervical Spinal Stenosis
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Musculoskeletal and connective tissue disorders
Connective Tissue Disorder
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Musculoskeletal and connective tissue disorders
Dupuytren's Contracture
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Musculoskeletal and connective tissue disorders
Fistula
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Musculoskeletal and connective tissue disorders
Foot Deformity
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Musculoskeletal and connective tissue disorders
Intervertebral Disc Protrusion
|
0.57%
6/1059 • Number of events 7 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.17%
2/1180 • Number of events 2 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Musculoskeletal and connective tissue disorders
Lupus-Like Syndrome
|
0.19%
2/1059 • Number of events 2 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Musculoskeletal and connective tissue disorders
Morphoea
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Musculoskeletal and connective tissue disorders
Muscular Weakness
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal Chest Pain
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.17%
2/1180 • Number of events 2 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Musculoskeletal and connective tissue disorders
Musculoskeletal Pain
|
0.19%
2/1059 • Number of events 2 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Musculoskeletal and connective tissue disorders
Osteoarthritis
|
0.28%
3/1059 • Number of events 3 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.25%
3/1180 • Number of events 4 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Musculoskeletal and connective tissue disorders
Osteochondrosis
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Musculoskeletal and connective tissue disorders
Osteoporosis
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Musculoskeletal and connective tissue disorders
Osteoporotic Fracture
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Musculoskeletal and connective tissue disorders
Pain In Extremity
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Musculoskeletal and connective tissue disorders
Periarthritis
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Musculoskeletal and connective tissue disorders
Pseudarthrosis
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Musculoskeletal and connective tissue disorders
Psoriatic Arthropathy
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Musculoskeletal and connective tissue disorders
Sacroiliitis
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Musculoskeletal and connective tissue disorders
Spinal Column Stenosis
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Musculoskeletal and connective tissue disorders
Spinal Disorder
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Musculoskeletal and connective tissue disorders
Spondylitis
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Musculoskeletal and connective tissue disorders
Spondyloarthropathy
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Musculoskeletal and connective tissue disorders
Synovitis
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Musculoskeletal and connective tissue disorders
Systemic Lupus Erythematosus
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Adenocarcinoma Of Colon
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Astrocytoma
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
B-Cell Lymphoma
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Bladder Cancer
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Breast Cancer
|
0.38%
4/1059 • Number of events 4 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Cholangiocarcinoma
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Cholesteatoma
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Clear Cell Sarcoma Of Soft Tissue
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Colon Cancer
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.25%
3/1180 • Number of events 3 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Colon Neoplasm
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Colorectal Cancer
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Glioblastoma
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Glioma
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Haemangioma
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Hepatic Cancer
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Intraductal Proliferative Breast Lesion
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung Adenocarcinoma Metastatic
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Lung Neoplasm Malignant
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Malignant Melanoma
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases To Bone
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases To Large Intestine
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Metastases To Liver
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Neoplasm Malignant
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Oesophageal Carcinoma
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Prostate Cancer
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.25%
3/1180 • Number of events 3 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Rectal Cancer
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Rectal Cancer Metastatic
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Rectal Neoplasm
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Renal Cancer Recurrent
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Renal Cell Carcinoma
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Skin Cancer
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Small Cell Lung Cancer Metastatic
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Squamous Cell Carcinoma
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.17%
2/1180 • Number of events 6 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Teratoma
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Thyroid Cancer
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Uterine Leiomyoma
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Vaginal Cancer
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Nervous system disorders
Carpal Tunnel Syndrome
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.17%
2/1180 • Number of events 2 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Nervous system disorders
Central Nervous System Lesion
|
0.09%
1/1059 • Number of events 2 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Nervous system disorders
Cerebellar Infarction
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Nervous system disorders
Cerebellar Syndrome
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Nervous system disorders
Cerebral Infarction
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Nervous system disorders
Cerebral Ischaemia
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Nervous system disorders
Cerebrovascular Accident
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.25%
3/1180 • Number of events 3 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Nervous system disorders
Epilepsy
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Nervous system disorders
Gliosis
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Nervous system disorders
Headache
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Nervous system disorders
Hypoaesthesia
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Nervous system disorders
Migraine
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Nervous system disorders
Multiple Sclerosis
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Nervous system disorders
Neuropathy Peripheral
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Nervous system disorders
Optic Neuritis
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Nervous system disorders
Paraesthesia
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Nervous system disorders
Polyneuropathy
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Nervous system disorders
Pyramidal Tract Syndrome
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Nervous system disorders
Quadriparesis
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Nervous system disorders
Sciatica
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Nervous system disorders
Sedation
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Nervous system disorders
Seizure
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Nervous system disorders
Syncope
|
0.19%
2/1059 • Number of events 2 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Nervous system disorders
Transient Ischaemic Attack
|
0.19%
2/1059 • Number of events 2 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Nervous system disorders
Tremor
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Nervous system disorders
Trigeminal Neuralgia
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Pregnancy, puerperium and perinatal conditions
Abortion Spontaneous
|
0.47%
5/1059 • Number of events 5 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Pregnancy, puerperium and perinatal conditions
Delivery
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Pregnancy, puerperium and perinatal conditions
Eclampsia
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Pregnancy, puerperium and perinatal conditions
Foetal Death
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Pregnancy, puerperium and perinatal conditions
Haemorrhage In Pregnancy
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Pregnancy, puerperium and perinatal conditions
Labour Complication
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Pregnancy, puerperium and perinatal conditions
Labour Pain
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Pregnancy, puerperium and perinatal conditions
Placenta Praevia Haemorrhage
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Pregnancy, puerperium and perinatal conditions
Pregnancy
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.17%
2/1180 • Number of events 2 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Pregnancy, puerperium and perinatal conditions
Stillbirth
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Psychiatric disorders
Acute Psychosis
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Psychiatric disorders
Bipolar Disorder
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Psychiatric disorders
Depression
|
0.66%
7/1059 • Number of events 7 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Psychiatric disorders
Eating Disorder
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Psychiatric disorders
Major Depression
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Psychiatric disorders
Mental Fatigue
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Psychiatric disorders
Mental Status Changes
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Psychiatric disorders
Psychotic Disorder
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Psychiatric disorders
Sleep Disorder
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Psychiatric disorders
Suicide Attempt
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Renal and urinary disorders
Acute Kidney Injury
|
0.19%
2/1059 • Number of events 2 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.17%
2/1180 • Number of events 2 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
1.0%
3/296 • Number of events 3 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Renal and urinary disorders
Bladder Diverticulum
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Renal and urinary disorders
Bladder Neck Obstruction
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Renal and urinary disorders
Calculus Bladder
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Renal and urinary disorders
Calculus Urinary
|
0.19%
2/1059 • Number of events 2 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Renal and urinary disorders
Chronic Kidney Disease
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Renal and urinary disorders
Haematuria
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Renal and urinary disorders
Hydronephrosis
|
0.19%
2/1059 • Number of events 2 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Renal and urinary disorders
Nephritis
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Renal and urinary disorders
Nephrolithiasis
|
0.28%
3/1059 • Number of events 3 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.17%
2/1180 • Number of events 2 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Renal and urinary disorders
Nephropathy
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Renal and urinary disorders
Renal Colic
|
0.28%
3/1059 • Number of events 3 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Renal and urinary disorders
Renal Failure
|
0.19%
2/1059 • Number of events 2 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Renal and urinary disorders
Renal Infarct
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Renal and urinary disorders
Stress Urinary Incontinence
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Renal and urinary disorders
Tubulointerstitial Nephritis
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Renal and urinary disorders
Ureteric Stenosis
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Renal and urinary disorders
Ureterolithiasis
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Renal and urinary disorders
Urethral Stenosis
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Renal and urinary disorders
Urinary Retention
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.17%
2/1180 • Number of events 2 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Reproductive system and breast disorders
Cervical Dysplasia
|
0.28%
3/1059 • Number of events 4 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Reproductive system and breast disorders
Endometriosis
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Reproductive system and breast disorders
Female Genital Tract Fistula
|
0.09%
1/1059 • Number of events 3 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Reproductive system and breast disorders
Noninfective Oophoritis
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Reproductive system and breast disorders
Ovarian Cyst
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Reproductive system and breast disorders
Perineal Fistula
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Reproductive system and breast disorders
Prostatitis
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Respiratory, thoracic and mediastinal disorders
Respiratory Failure
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Reproductive system and breast disorders
Scrotal Mass
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Reproductive system and breast disorders
Vaginal Fistula
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Respiratory, thoracic and mediastinal disorders
Acute Pulmonary Oedema
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Respiratory, thoracic and mediastinal disorders
Alveolitis
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.17%
2/1180 • Number of events 2 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Respiratory, thoracic and mediastinal disorders
Bronchial Oedema
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Respiratory, thoracic and mediastinal disorders
Bronchospasm
|
0.19%
2/1059 • Number of events 2 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Respiratory, thoracic and mediastinal disorders
Chronic Obstructive Pulmonary Disease
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.17%
2/1180 • Number of events 3 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Respiratory, thoracic and mediastinal disorders
Tonsillar Inflammation
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.17%
2/1180 • Number of events 3 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Respiratory, thoracic and mediastinal disorders
Emphysema
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Respiratory, thoracic and mediastinal disorders
Haemoptysis
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Respiratory, thoracic and mediastinal disorders
Hyperventilation
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Respiratory, thoracic and mediastinal disorders
Laryngeal Oedema
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Respiratory, thoracic and mediastinal disorders
Lung Consolidation
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Respiratory, thoracic and mediastinal disorders
Oropharyngeal Pain
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Respiratory, thoracic and mediastinal disorders
Pleural Effusion
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Respiratory, thoracic and mediastinal disorders
Pneumothorax
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Respiratory, thoracic and mediastinal disorders
Productive Cough
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary Embolism
|
0.28%
3/1059 • Number of events 3 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.42%
5/1180 • Number of events 7 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.68%
2/296 • Number of events 2 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary Mass
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Respiratory, thoracic and mediastinal disorders
Pulmonary Sarcoidosis
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.68%
2/296 • Number of events 2 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Skin and subcutaneous tissue disorders
Acne
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Skin and subcutaneous tissue disorders
Dermatitis Bullous
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Skin and subcutaneous tissue disorders
Lentigo
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Skin and subcutaneous tissue disorders
Pruritus
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Skin and subcutaneous tissue disorders
Psoriasis
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Skin and subcutaneous tissue disorders
Pyoderma Gangrenosum
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Skin and subcutaneous tissue disorders
Rash
|
0.28%
3/1059 • Number of events 3 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Skin and subcutaneous tissue disorders
Solar Lentigo
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Skin and subcutaneous tissue disorders
Urticaria
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Surgical and medical procedures
Abdominoplasty
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Surgical and medical procedures
Colectomy
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Surgical and medical procedures
Female Sterilisation
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Surgical and medical procedures
Ileostomy
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Surgical and medical procedures
Ileostomy Closure
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Vascular disorders
Aortic Stenosis
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Vascular disorders
Circulatory Collapse
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Vascular disorders
Deep Vein Thrombosis
|
0.28%
3/1059 • Number of events 4 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.25%
3/1180 • Number of events 3 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Vascular disorders
Embolism Arterial
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Vascular disorders
Haematoma
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Vascular disorders
Haemorrhage
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Vascular disorders
Hypertensive Crisis
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Vascular disorders
Hypotension
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Vascular disorders
Hypovolaemic Shock
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Vascular disorders
Iliac Artery Occlusion
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 2 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Vascular disorders
Intermittent Claudication
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Vascular disorders
Orthostatic Hypotension
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Vascular disorders
Pelvic Venous Thrombosis
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Vascular disorders
Peripheral Arterial Occlusive Disease
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.34%
1/296 • Number of events 2 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Vascular disorders
Peripheral Ischaemia
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Vascular disorders
Peripheral Vascular Disorder
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 3 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Vascular disorders
Shock Haemorrhagic
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Vascular disorders
Subclavian Vein Thrombosis
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Vascular disorders
Temporal Arteritis
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.08%
1/1180 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Vascular disorders
Thrombosis
|
0.00%
0/1059 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.17%
2/1180 • Number of events 2 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Vascular disorders
Vasculitis
|
0.09%
1/1059 • Number of events 1 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Vascular disorders
Venous Thrombosis
|
0.19%
2/1059 • Number of events 2 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/1180 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
0.00%
0/296 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
Other adverse events
| Measure |
Remicade Group
n=1059 participants at risk
Participants with no prior exposure to Remicade or who have been treated with Remicade in the past, who at the time of enrollment are scheduled to receive Remicade within 30 days of the Baseline Visit. Participants who have been treated in the past with Remicade must have a Remicade-free interval of no less than 90 days from the date of the next expected infusion.
|
Standard Therapy Group
n=1180 participants at risk
Participants who are scheduled to receive standard therapy (defined as initiation or dose-increase of corticosteroids and/or immunosuppressants) that does not include Remicade. Standard therapy participants must not have previously received Remicade for UC or any other condition.
|
Switched to Remicade Group
n=296 participants at risk
Participants who started in the Standard Therapy Group but switched over to Remicade. AEs were counted after the switch to Remicade.
|
|---|---|---|---|
|
Gastrointestinal disorders
Colitis Ulcerative
|
20.1%
213/1059 • Number of events 314 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
12.3%
145/1180 • Number of events 207 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
17.2%
51/296 • Number of events 75 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Infections and infestations
Nasopharyngitis
|
6.0%
64/1059 • Number of events 79 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
1.9%
23/1180 • Number of events 25 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
3.0%
9/296 • Number of events 9 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
|
Musculoskeletal and connective tissue disorders
Arthralgia
|
9.0%
95/1059 • Number of events 116 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
2.0%
24/1180 • Number of events 28 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
5.7%
17/296 • Number of events 20 • Up to 5 years
All enrolled participants.The Remicade and Standard Therapy Groups are the number of participants who enrolled at the start of the study (N=2239). The Switched to Remicade group are the subset of participants in the Standard Therapy Group, who switched to Remicade.
|
Additional Information
Senior Vice President, Global Clinical Development
Merck Sharp & Dohme Corp.
Phone: 1-800-672-6372
Email: [email protected]
Results disclosure agreements
- Principal investigator is a sponsor employee The investigator agrees to provide to the sponsor 45 days prior to submission for publication or presentation, review copies of abstracts or manuscripts for publication that report any results of the study. The sponsor shall have the right to review and comment with respect to publications, abstracts, slides, and manuscripts and the right to review and comment on the data analysis and presentation.
- Publication restrictions are in place
Restriction type: OTHER